Search Results - "Pavlick, A. C."

Whole body PET/CT for initial staging of choroidal melanoma by Finger, P T, Kurli, M, Reddy, S, Tena, L B, Pavlick, A C

“…Aim: To investigate the value of whole body positron emission tomography/computed tomography (PET/CT) in screening for metastatic choroidal melanoma in…”
Get full text

Proteasome Inhibition With Bortezomib (PS-341): A Phase I Study With Pharmacodynamic End Points Using a Day 1 and Day 4 Schedule in a 14-Day Cycle by HAMILTON, A. L, EDER, J. P, KINCHLA, N, BOYDEN, J, YEE, H, ZELENIUCH-JACQUOTTE, A, WRIGHT, J, ELLIOTT, P, ADAMS, J, MUGGIA, F. M, PAVLICK, A. C, CLARK, J. W, LIEBES, L, GARCIA-CARBONERO, R, CHACHOUA, A, RYAN, D. P, SOMA, V, FARRELL, K

“…We performed a phase I study of a day (D) 1 and D4 bortezomib administration once every 2 weeks to determine the recommended phase II dose and toxicity…”
Get full text

A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancer by Veeraraghavan, J., De Angelis, C., Mao, R., Wang, T., Herrera, S., Pavlick, A.C., Contreras, A., Nuciforo, P., Mayer, I.A., Forero, A., Nanda, R., Goetz, M.P., Chang, J.C., Wolff, A.C., Krop, I.E., Fuqua, S.A.W., Prat, A., Hilsenbeck, S.G., Weigelt, B., Reis-Filho, J.S., Gutierrez, C., Osborne, C.K., Rimawi, M.F., Schiff, R.

“…HER2-positive (+) breast cancers, defined by HER2 overexpression and/or amplification, are often addicted to HER2 to maintain their malignant phenotype. Yet,…”
Get full text

Endoscopic ultrasound in the evaluation of gastric small lymphocytic mucosa-associated lymphoid tumors by Pavlick, A C, Gerdes, H, Portlock, C S

“…Low-grade, small lymphocytic lymphomas of the mucosa-associated lymphoid tissue (MALT) have recently been shown to be associated with Helicobacter pylori…”
Get more information

Primary choroidal melanoma followed by two metachronous ipsilateral ocular metastases by Finger, P. T., Yin, C. T., Pavlick, A. C., Farhat, N.

“…Purpose . To describe two ipsilateral, metachronous, ocular choroidal melanoma metastases. Material and methods . A 64-year-old choroidal melanoma patient was…”
Get full text

1318PPhase II study of 2 dosing regimens of cemiplimab, a human monoclonal anti–PD-1, in metastatic cutaneous squamous cell carcinoma (mCSCC) by Rischin, D, Lim, A M, Schmults, C D, Khushalani, N I, Hughes, B G, Schadendorf, D, Dunn, L A, Chang, A L S, Hauschild, A, Ulrich, C, Eigentler, T, Migden, M R, Pavlick, A C, Geiger, J, Stankevich, E, Li, S, Lowy, I, Fury, M G, Guminski, A

“…Abstract Background Cemiplimab-rwlc is the only US FDA-approved treatment for patients (pts) with advanced CSCC. The primary analysis of a weight-based regimen…”
Get full text

Final overall survival for KEYNOTE-002: pembrolizumab (pembro) versus investigator-choice chemotherapy (chemo) for ipilimumab (ipi)-refractory melanoma by Hamid, O., Puzanov, I., Dummer, R., Schachter, J., Daud, A., Schadendorf, D., Blank, C., Cranmer, L.D., Robert, C., Pavlick, A.C., Gonzalez, R., Hodi, F.S., Ascierto, P.A., Salama, A., Margolin, K.A., Gangadhar, T.C., Wei, Z., Ebbinghaus, S.W., Ibrahim, N., Ribas, A.

Get full text

PD-L1 expression as a biomarker for nivolumab (NIVO) plus ipilimumab (IPI) and NIVO alone in advanced melanoma (MEL): A pooled analysis by Long, G.V., Larkin, J., Ascierto, P.A., Hodi, F.S., Rutkowski, P., Sileni, V., Hassel, J., Lebbe, C., Pavlick, A.C., Wagstaff, J., Schadendorf, D., Dummer, R., Hogg, D., Haanen, J.B.A.G., Corrie, P., Hoeller, C., Horak, C., Wolchok, J., Robert, C.

Get full text

A phase 2 study of glembatumumab vedotin (GV), an antibody-drug conjugate (ADC) targeting gpNMB, in advanced melanoma by Ott, P.A., Pavlick, A.C., Johnson, D.B., Hart, L.L., Infante, J.R., Luke, J.J., Lutzky, J., Rothschild, N., Spitler, L., Cowey, C.L., Alizadeh, A., Salama, A., He, Y., Bagley, R.G., Zhang, J., Hamid, O.

Get full text

Novel therapeutic agents under investigation for malignant melanoma by Pavlick, Anna C, Adams, Sylvia, Fink, Matthew A, Bailes, Amanda

“…Malignant melanoma presents a therapeutic challenge. Patients at high risk for recurrence (stage III) are eligible for adjuvant treatment with IFN-alpha or may…”
Get more information

Does incidence of rash predict treatment response to lapatanib in breast cancer? by Parma, J. M., Pavlick, A. C., Chang, J. C. N., Rimawi, M. F., Trivedi, M.

“…Abstract only…”
Get full text

Distinguishing between nodular and superficial spreading melanoma using specific microRNA alterations by Poliseno, L., Haimovic, A., Hanniford, D., Segura, M. F., Christos, P. J., Shapiro, R. L., Pavlick, A. C., Berman, R. S., Hernando, E., Zavadil, J., Osman, I.

“…Abstract only…”
Get full text

Safety and survival analysis of ipilimumab therapy in patients with stable asymptomatic brain metastases by Heller, K. N., Pavlick, A. C., Hodi, F. S., Thompson, J. A., Margolin, K. A., Lawrence, D. P., McDermott, D. F., Samlowski, W. E., Michener, T., Karasarides, M.

“…Abstract only…”
Get full text

An analysis of sera-based microRNAs as biomarkers of recurrence in melanoma by Friedman, E. B., Shang, S., Vega-Saenz de Miera, E., Ma, M. W., Berman, R. S., Shapiro, R. L., Pavlick, A. C., Hernando, E., Shao, Y., Osman, I.

“…Abstract only…”
Get full text

MLN4924, an investigational NEDD8-activating enzyme (NAE) inhibitor, in patients (pts) with metastatic melanoma: Results of a phase I study by Bhatia, S., Hamid, O., Pavlick, A. C., Mulligan, G., Smith, P. G., Pickard, M. D., Shultz, M., Walker, R. M., Dezube, B., O'Day, S.

“…Abstract only…”
Get full text

Impact of population genetic substructure on association studies and risk assessment for melanoma by Lobach, I., Belitskaya-Levy, I., Goldberg, J. D., Ostrer, H., Berman, R. S., Pavlick, A. C., Shapiro, R. L., Osman, I., Manga, P.

“…Abstract only…”
Get full text

Abraxane, temozolomide, and oblimersen (The ATG Trial): A final report of toxicity and clinical efficacy in metastatic melanoma patients with normal lactate dehydrogenase (LDH) by Chang, J. L., Ott, P. A., Sorlie, C., Escano, C., Yepes, E., Mendoza, S., Gandhi, A., Liebes, L., Pavlick, A. C.

“…Abstract only…”
Get full text

Primary melanoma features associated with increased risk of brain metastasis by Ma, M. W., Qian, M., Lackaye, D., Berman, R. S., Shapiro, R. L., Pavlick, A. C., Golfinos, J., Parker, E., Hernando, E., Shao, Y., Osman, I.

“…Abstract only…”
Get full text

Oblimersen 1-hour IV infusion in combination with temozolomide and albumin-bound paclitaxel in patients with advanced melanoma by Ott, P. A., Madden, K. M., Kannan, R., Yee, H., Mendoza, S., Dubose, B., Liebes, L., Pavlick, A. C.

“…Abstract only…”
Get full text

Prognostic factors for survival in patients with stage (stg) IV malignant melanoma (MM) by Seetharamu, N., Hamilton, H., Tu, T., Christos, P., Osman, I., Pavlick, A. C.

“…Abstract only 9072 Background: Prognosis for survival in MM is not uniform with some pts being long-term survivors. Identifying this subset of pts may have…”
Get full text